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Abstract
The adoption and use of digital forms of direct-to-consumer advertising (also known as “eDTCA”) is on the rise. At 
the same time, the universe of eDTCA is expanding, as technology on Internet-based platforms continues to evolve, 
from static websites, to social media, and nearly ubiquitous use of mobile devices. However, little is known about 
how this unique form of pharmaceutical marketing impacts consumer behavior, public health, and overall healthcare 
utilization. The study by Kim analyzing US Food and Drug Administration (FDA) notices of violations (NOVs) and 
warning letters regarding online promotional activities takes us in the right direction, but study results raise as many 
questions as it does answers. Chief among these are unanswered concerns about the unique regulatory challenges 
posed by the “disruptive” qualities of eDTCA, and whether regulators have sufficient resources and oversight powers 
to proactively address potential violations. Further, the globalization of eDTCA via borderless Internet-based 
technologies raises larger concerns about the potential global impact of this form of health marketing unique to only 
the United States and New Zealand. Collectively, these challenges make it unlikely that regulatory science will be able 
to keep apace with the continued rapid evolution of eDTCA unless more creative policy solutions are explored. 
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A recent study by Kim conducted a content analysis of notices of violations (NOVs) and warning letters issued by the U.S. Food and Drug Administration (FDA) 
over a 10-year period (2005-2014).1 The study was carried out 
in order to identify common regulatory, public health, and 
patient safety challenges unique to online direct-to-consumer 
advertising (DTCA) of prescription drugs, a form of health 
marketing that is experiencing rapid growth.2,3 Kim’s results 
support findings from prior studies–namely that DTCA does 
not adequately communicate information to consumers in a 
fair and balanced manner in relation to risks versus benefits –
and that this challenge extends beyond traditional media (eg, 
print, television, radio) into digital advertising.1,4,5 However, 
though Kim’s study introduces needed evidence on the topic, 
clinicians, consumers, and policy-makers continue to remain 
unaware of the changing dynamics of DTCA in the evolving 
digital media environment. 
Specifically, Kim’s study raises several concerns about how 
online promotional activities can negatively impact public 
health and consumer safety. This includes its potential use 
in off-label promotion activities (based on study findings 
showing that industry sponsored links on search engines 
did not provide adequate drug indication information), 
how the dynamic nature of these technologies can influence 
consumers differently than traditional forms of promotion, 
and how marketers may be changing DTCA tactics in order 
to leverage the power of these platforms to directly reach and 
build relationships with consumers in new and different ways.
Further, the study raises more fundamental questions of 
whether regulatory responses by FDA are responsive and 
adaptive enough to address the inherent challenges faced 
by a universe of digital and Internet-based forms of DTCA 
(collectively referred to as “eDTCA”) that have the ability to 
transcend US borders via the Internet.6,7 In response, this 
commentary highlights some of the unique challenges faced 
by the emergence of eDTCA that warrant further research 
and exploration. It ends with a discussion about emerging 
challenges on the horizon, given the ability of eDTCA to 
globalize, and why regulatory science is unlikely to keep apace 
with the continued rapid growth and evolution of eDTCA.
Future Growth of eDTCA
According to a recent report by the IMS Institute for 
Healthcare Informatics, global spending on medicines will 
reach $1.4 trillion by 2020, indicating that total pharmaceutical 
expenditures will undergo double-digit growth for the next 
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half decade.8 Though “pharmerging” markets (including 
emerging economies of India, China, Brazil, and Indonesia) 
will likely account for a significant portion of this growth, 
the United States nevertheless continues to lead all countries 
in total prescription drug spending and utilization.8,9 This 
includes a 13% increase in US prescription drug expenditures 
in 2014 (totaling an estimated $374 billion), representing the 
largest percent increase since 2001.10 Growth is attributed to 
the high cost of new drugs on the market (including the new 
hepatitis C drug sofosbuvir manufactured by Gilead Sciences 
and other expensive cancer and autoimmune therapeutics), 
fewer patent expirations for branded drugs, increased 
spending on specialty drugs, and the possible impact of the 
Affordable Care Act (ACA) on increased healthcare coverage 
and prescription drug spending.10
Coincidentally, the United States – the largest consumer 
market for prescription drugs – is one of only two developed 
countries (the other New Zealand) that currently legally 
allows DTCA.11 This means that continued growth in US 
national prescription drug spending will likely fuel further 
spending on DTCA, especially given increased scrutiny 
to physician-directed promotion due to transparency 
requirements enacted as part of the ACA.6,12,13 Within the 
overall category of DTCA, a recent study found that Internet-
based DTCA was the only subcategory that experienced rapid 
growth (an estimated 109% increase) from 2005-2009.2 Yet, 
the ascendance of eDTCA should come as no surprise, with 
surveys conducted by the Pew Research Center showing that 
72% of Internet users actively search for health information 
online.14 Hence, the combination of increased drug spending 
and widespread use of the Internet by consumers to search for 
health information, has created the perfect storm for eDTCA 
to emerge as a more prominent and influential form of health 
and drug marketing.6,15,16
Regulatory Challenges of eDTCA
The rise in the use of health information technology has been 
described as a “disruptive” phenomenon.17 eDTCA also reflects 
these same “disruptive” qualities in the context of health 
communications. Kim’s study reports that FDA characterizes 
eDTCA as highly interactive, rich in multimedia and user-
generated content, interacts socially with consumers, and that 
eDTCA campaigns are often strategically coordinated and 
interlinked through shared online resources.1 Yet, technology 
innovation and market disruption are difficult areas for 
regulators to proactively address through enforcement, policy 
and rule-making. FDA is no exception and has struggled 
to achieve the correct balance of regulatory oversight given 
the unique challenges associated with eDTCA and the 
constantly changing nature of Internet technologies. Instead 
of pursuing comprehensive regulation, FDA has relied on 
issuing draft non-binding industry guidance to address issues 
on a piecemeal basis including (1) responding to unsolicited 
requests about off-label information including via the Internet 
and social media (2011); (2) product name placement, size, 
and prominence in Internet advertising (2013); (3) voluntary 
correction of misinformation on the Internet and social media 
platforms by firms (2014); and (4) structuring promotion for 
Internet and social media platforms with character space 
limitations (eg, Twitter) (2014).18-21 Though draft guidance 
is aimed at providing regulatory clarity, it can also lead to 
confusion, hence necessitating the examination of NOVs/
warning letters in Kim’s study and others.22-25 
However, Kim’s piece does not fully assess the relationship 
between content of NOVs/warning letters and how it tracks 
with the timing of FDA regulatory guidance issued during 
the 10-year study period. This is an important component 
in assessing whether regulatory intervention (through the 
combination of warning/violation letters and issuance of 
industry guidance) has had its desired impact: primarily 
clarifying for manufacturers what forms of eDTCA content 
will trigger a violation, ensuring manufacturers correct 
existing deficiencies, and dissuading these activities in future 
marketing practices. Furthermore, NOVs/warning letters 
are likely not representative of past and ongoing eDTCA 
industry trends. Specifically, it is unclear how the FDA 
conducts surveillance and monitoring of eDTCA (including 
its sampling methodology for digital advertisements) and 
how it prioritizes enforcement activities through its Office of 
Prescription Drug Promotion (OPDP), especially since the 
OPDP has historically lacked necessary funding to carry out 
its operational mandates.22 
One striking example of the potential limitations of NOVs/
warning letters as a secondary data source in order to 
understand eDTCA trends is Kim’s finding that only two FDA 
actions targeted social media (both on Facebook.).1 This result 
seems peculiar especially given the high-degree of popularity 
of social media in health communications, prior studies that 
have reported near universal use of these platforms (including 
Facebook, Twitter, and YouTube) by large pharmaceutical 
firms, and another study that found a majority of eDTCA 
drug product claims emphasized benefits over risks.7,15,16 
Further, study findings that violations occurred simultaneous 
across several different industry digital assets (including 
sponsored search links, online videos, and on company 
websites) emphasizes the need to assess how the entire online 
environment is collectively being used to influence the 
consumer through exposure to different marketing channels, 
multimedia, and targeted messaging. 
Other minor findings in Kim’s study making up a smaller 
percentage of NOV/warning letter content characteristics 
should also raise alarms. This includes pharmaceutical 
companies directly contacting consumers via email (in the 
case of 2 letters analyzed) and their attempt to use these same 
consumers to propagate their DTCA via social media.1 This 
blunt form of “marketer controlled” DTCA by attempting to 
use patients as “third-party endorsers” raises privacy concerns 
regarding the use of protected health information (PHI) and 
could possibly violate the US Health Insurance Portability and 
Accountability Act (HIPPA) (if the information is categorized 
as PHI and the patient has not adequately consented to use and 
disclosure for the purposes of marketing.) These violations 
may also be a byproduct of a DTCA channel that has been 
largely neglected in pharmaceutical marketing research: the 
use of branded and unbranded patient engagement portals 
operated under the control of a pharmaceutical firm (or 
their intermediaries) that create online environments where 
manufacturers can control interactions between current and 
prospective consumers.26 These patient engagement portals 
directly sign up consumers (usually via email registration), may 
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offer free services or treatment guidance, and often include 
online patient coaches/advocates, but also simultaneously 
serve as veiled marketing platforms for eDTCA.26 
Lastly, a set of new violations added in the study’s analysis 
(ie, indication information and violation of product labeling), 
highlights the dangerous possibility that manufacturers 
may be engaged in illegal off-label promotion by failing to 
provide adequate information on drug dosage or the specific 
patient population that can be treated per the approved FDA 
indication.1,27,28 Though manufacturers may argue that space 
and character limitations (such as sponsored search engine 
links) preclude them from communicating this information 
effectively, omission of such information appears to be in direct 
violation of FDA regulations that prohibit manufacturers from 
promoting drugs off-label.29,30 This risk could be accentuated 
by a recent 2015 federal district court decision in Amarin vs. 
FDA, that ruled that manufacturers have the constitutionally 
protected right to engage in “truthful” and “non-misleading” 
off-label communication, a decision that may embolden 
industry use of eDTCA for off-label promotion.30-33
Global Implications 
Another important concern raised by Kim is the risk that 
eDTCA communication that violates FDA rules, guidance and 
regulations, could also impact populations outside the United 
States. Specifically, Kim notes that Facebook pages subject 
to FDA warning/violation letters appeared to be accessible 
to non-US consumers.1 This observation confirms findings 
from prior studies that have identified lack of US domestic 
DTCA regulation as a enabling factor for global dissemination 
of DTCA via Internet-based technologies.6,7,9,16,34 Currently, 
there are no appropriate controls to limit international DTCA 
dissemination, a responsibility that arguably falls on the 
shoulders of drug manufacturers and the FDA who act to 
generate and regulate eDTCA content.
In response to this clear regulatory gap, policy experimentation 
emanating from Canada may represent a future strategy to 
address the globalization of eDTCA. Canadian researchers 
have long recognized the potential public health risks 
associated with the international spread of DTCA, as 
originally identified in studies examining the impact of cross-
border transmission of US TV DTCA satellite broadcasts 
on prescription drug utilization and patient safety.35-37 In 
addition, Canadian stakeholders have begun to recognize the 
unique threat posed by eDTCA for Canadian public health.15 
As an example, In 2013, the British Columbia Medical 
Association and others called for Health Canada to appoint a 
watchdog to block DTCA ads transmitted via the Internet and 
social media.38 This could theoretically be accomplished by 
implementing technical tools already utilized for preventing 
access to Internet content in certain jurisdictions, such as 
blocking foreign IP addresses or requiring Internet service 
providers/manufacturers to limit user access and online 
transmission.38 Such an approach is consistent with current 
law as well as policy provisions generally prohibiting DTCA 
in Canada and a host of other countries.9,15,16,36 
Conclusions
With pharmaceutical spending enjoying strong growth and 
millions of people searching for health information online, 
eDTCA likely represents the next frontier for pharmaceutical 
marketing.13 Yet this marketing medium remains highly 
controversial given the rising costs of prescription drugs, a 
point underscored by a recent vote by the American Medical 
Association in support of a DTCA ban.39 Despite eDTCA’s 
rapid growth and maturation, regulatory responses seem to 
be several steps behind industry activities, who can no longer 
afford to wait for FDA to give them sufficient guidance on how 
to engage with their patients online.15,16 This includes revised 
2015 FDA draft guidance that calls for the use of a “Drug 
Facts” box or Q&A to better communicate risk information 
to consumers.40 Specifically, revised draft guidance appears 
to continue FDA’s antiquated trend of overemphasizing 
traditional media in DTCA regulatory efforts and may lack 
flexibility in addressing the dynamic challenges faced by 
eDTCA.11,40 As categories of eDTCA continue to expand 
in a 21st century digital health landscape populated by 
growing numbers of “e-patients,” it is crucial that clinicians, 
researchers, policy-makers, and the public better understand 
the true scope and influence of eDTCA and how it impacts 
how they “consume” health.
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